ABT-737

Catalog No.S1002

ABT-737 Chemical Structure

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 384 In stock
USD 120 In stock
USD 200 In stock
USD 570 In stock
USD 970 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 90 Publications

16 Customer Reviews

  • Cardiomyocytes transduced with or without Ad-Mst1 were treated with ABT-737 (0, 0.1, 1, 10 uM) for 12 hours. Representative immunoblots with antibodies to p62/SQSTM1, LC3 and GAPDH are shown.

    Nat Med 2013 19(11), 1478-88. ABT-737 purchased from Selleck.

    BCL-XL mediates human neutrophil survival. PMNs were preincubated with the BH3 mimetic ABT-737 (1–10 μM), then cultured in normoxia (gray bars) with or without GM-CSF (500 U/ml) or hypoxia (white bars)or 20 hours, and apoptosis was assessed by morphology (n = 4).

     

     

    J Clin Invest 2011 121, 1053-1063. ABT-737 purchased from Selleck.

  • Release of mitochondrial cytochrome c and loss of mitochondrial membrane potential after exposure to ABT-737 (100nM) for 2 hours were assessed by immunohistochemistry and staining with TMRE (red, top panels) and anti-CD41/FITC (green, top panels). Bar represents 5 um. Note that control cells display spreading on glass slides, whereas ABT-737-treated cells do not.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

    Platelets were incubated in HBS with or without ABT-737 (100nM) for 2 hours before analysis by immunohistochemistry and confocal microscopy. Actin was stained using phalloidin/Alexa-488 (green), and tubulin was stained using anti-tubulin/phycoerythrin (red). Bar represents 5 uM.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

  • (B) The sensitivity (LD50) of CLL cells, assessed by annexin V staining after 48 h of treatment with ABT‐737, ABT‐263 or ABT‐199, was plotted against the pBcl‐2/Bcl‐2, Mcl‐1/Bcl‐2 and (pBcl‐2 + Mcl‐1)/Bcl‐2 ratios. Relative protein quantification was carried out with kodak carestream molecular imaging software and normalized to β‐actin. Spearman's correlation (r) and P values are shown. Data shown are representative of five independent experiments.

    Br J Pharmacol, 2016, 173(3):471-83. ABT-737 purchased from Selleck.

    Analysis of SW480 and SW620 cell sensitivity to the BH3-mimetic ABT-737. (a, b) Percentage of apoptosis in adherent or suspended SW480 (a) or SW620 (b) cells cultured in the presence (ABT-737) or absence (ctrl) of ABT-737 (1 uM).

    Cell death dis 2013 4, e801. ABT-737 purchased from Selleck.

  • Bcl-XL/Bcl-2 inhibitor ABT-737 aggravates the proapoptotic effects of IL-1IFN-. INS-1E cells were transfected with single or smart Pool PUMA siRNAs and exposed to ABT-737 for 24 h. At this time point, cell death was measured by HO/PI, n  3. *, p  0.05; **, p  0.01.
     

     

     

    J Biol Chem 2010 285, 19919-19920. ABT-737 purchased from Selleck.

    Effect of ABT-737 on the cell viability of CCRF-CEM cells by treatments of AY4 (10 μg/ml), TRAIL (0.5 μg/ml), SAHA (1 μM),VPA (1 mM), or ABT-737 (10 μM) alone or in combination for 24 h prior to MTT assay.

     

     

    Apoptosis 2010 15, 1256-1269. ABT-737 purchased from Selleck.

  • Upper panel ABT-737 inhibits TFK-1 and EGI-1 cell growth.Cells were exposed to ABT-737 at a concentration ranging from 1 to 50 lM. Following 72 h of incubation, growth inhibition was analyzed by crystal violet assay. Dose–effect plot of ABT-737 treatment is presented.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

    Lower panel detection of PARP-1, cleaved caspase-9 and caspase-3, BCL-2 and MCL-1 in TFK-1 and EGI-1 cells after 72 h of ABT-737 treatment (1, 3, 10, 25,50 μM). Cell lysates were analyzed on Western blotting.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

  • 3 μM ABT737 inhibited growth and viability of TF-1 cells and potentiated proapoptotic effects of 1 μM BIO after 72 hours treatment. TF-1 cells treated with both drugs exhibited more apoptotic cells compared to those treated with each single drug. ABT737 abrogated the protection from BIO-induced apoptosis provided by MS5 coculture.

     

     

    Exp Hematol 2010 38, 908-921. ABT-737 purchased from Selleck.

    GSIXII synergized with ABT-737 to trigger apoptosis in breast cancer cells . Breast cancer cell lines were incubate d for 48 hours with 10μM GSIXII or DMSO (Ct) in combination or not with ABT-737, 1 μM. Then apoptosis was evaluated with Apo2.7 or Annexin-V staining and flow-cytometry analysis. Represented data are the means of positive cells ± SEM, from three independent experiments.(A) Suboptimal concentrations of GSIXII (5 μM) and 1 μM ABT-737 were used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with mock-treated condition. (B) The 20 μM SAHM1 was used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with the mock-treated condition.

    Biochem Biophys Res Commun 2013 408, 344-9. ABT-737 purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2012 408, 344-9. ABT-737 purchased from Selleck.

    The combined use of ABT-737 and sorafenib changes the apoptotic effect. MC-3 cells were treated with the indicated compounds for 48 h. (A) Nuclear condensation and fragmentation were evaluated in DAPI-stained cells as described in the Materials and Methods (X400). (B) Live (green) and dead (red) cells were qualified using the Live/dead assay kit as described in the Materials and Methods (X200). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Arch Oral Biol, 2017, 73:1-6. ABT-737 purchased from Selleck.

  • MEF wt and MEF Mcl-1 ko mice activating active caspase-3 using 1um ABT for 24h

     

     

    Dr. Arnim Weber of Medizinische Mikrobiologie und Hygiene Universitatsklinikum Freiburg. ABT-737 purchased from Selleck.

    MDB-MA-231 cells were exposed to 30 um cisplatin in the absence or in thepresence of 100nm ABT-737.The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. ABT-737 purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
Features First-generation inhibitor of anti-apoptotic Bcl-2 proteins.
Targets
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
Bcl-B [1]
(Cell-free assay)
Bfl-1 [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50) >10 μM(EC50)
In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. [1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. [2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. [3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. [4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OCI-Ly1  NXzxR|MxS2WubDDWbYFjcWyrdImgRZN{[Xl? MViyOVAhdk4EoB?= M1XLeVczKGh? NU[1U|J6TE2VTx?= MU\jZZV{\WRiOUelJIxwe3Nib3[geoli[mmuaYT5JIlvKGOnbHzzJJRz[W6|ZnXjeIVlKHerdHigRmNNPiC|aWLORS=> NX7YdmZtOjZ4NUeyPFg>
KG1a Ml;rR4VtdCCYaXHibYxqfHliQYPzZZk> NIHSe3IxNTFyIN88US=> NHzH[4wzPCCq M3qzU2ROW09? NH3WT4dKSzVyPUeuOlgh|ryPLDDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NGLtOlIzPjV3MkexNi=>
Kasumi-1 NGfuWGtE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVmwMVExKM7:TR?= M33aOlI1KGh? M3K1T2ROW09? NGLIdYRKSzVyPUSuPFch|ryPLDDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXnwTVlZOjZ3NUK3NVI>
KG1a NV3jOol2SXCxcITvd4l{KEG|c3H5 MnLsNE0yOCEQvF2= MkmyNlQhcA>? NIrldJdFVVOR M4fnOYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{DzNlI3PTV{N{Gy
Kasumi-1 Mn;mRZBweHSxc3nzJGF{e2G7 NF60Z|ExNTFyIN88US=> NHjjfmszPCCq NXOzPINsTE2VTx?= NHP1NFlqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3ezdlI3PTV{N{Gy
MC-3  Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvvUms2NzFyL{KwJO69VQ>? MUmyOEBp M1;Jc2ROW09? M1P3fYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NH\sO2IzPjR2N{[xOS=>
HN22  M2PTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[yMlUwPy53L{KyMlUh|ryP NYG3XItKOjRiaB?= NGrqTmpFVVOR MlqybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mnz2NlY1PDd4MUW=
MC-3  NFPjbGJCeG:ydH;zbZMhSXO|YYm= NWH2bm44PS9zMD:yNEDPxE1? M3K4VFI1KGh? NVT5c4ZOTE2VTx?= M3PjTIlv\HWlZYOgZ4F{eGG|ZT3t[YRq[XSnZDDhdI9xfG:|aYO= NF3ZcoUzPjR2N{[xOS=>
HN22  M1\tOWFxd3C2b4Ppd{BCe3OjeR?= NFXWZpEzNjVxNz61M|IzNjVizszN MWSyOEBp NHP5XIpFVVOR NHfaRohqdmS3Y3XzJINie3Cjc3WtcYVlcWG2ZXSgZZBweHSxc3nz MWGyOlQ1PzZzNR?=
MOLT-4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfodXdkOTBvNUCwNEBvVQ>? MYi3NkBp M1f0W2ROW09? M4[5Z2lEPTB;MD6xPVgh|ryP M3\mVVI3Ozl{M{Oy
RS4;11 NEXmfYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVmxNE02ODByIH7N MlzmO|IhcA>? MVzEUXNQ MWfJR|UxRTBwMECyJO69VQ>? MX:yOlM6OjN|Mh?=
JURKAT NIDFS|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPZNVAuPTByMDDuUS=> NYTuO4xlPzJiaB?= NXfneIRJTE2VTx?= MUPJR|UxRTZ4IN88US=> NGn6VY0zPjN7MkOzNi=>
CEM R MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jRWVExNTVyMECgcm0> MlTVO|IhcA>? NE\2S|JFVVOR MkG0TWM2OD13LkSg{txO MoDnNlY{QTJ|M{K=
CEM S MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3BT5cyOC13MECwJI5O NY\SVmtIPzJiaB?= MlrsSG1UVw>? MXXJR|UxRTF{LkGg{txO NX\zS2ROOjZ|OUKzN|I>
MOLT-4 MWLBdI9xfG:|aYOgRZN{[Xl? M1zaOlExNTFyMECgcm0> MXeyOEBp NHjn[ZpFVVOR MmDGZ4F2e2W|IITo[UBkdGWjdnHn[UBw\iCEY3ytNkBidmRidHjlJIRwf26{ZXf1cIF1cW:wIH;mJGJkdC26TDDhcoQhVWOuLUG= NYHocIk5OjZ|OUKzN|I>
CEM S M4LJfmFxd3C2b4Ppd{BCe3OjeR?= NWjmOHV3OTBvMUCwNEBvVQ>? NFm3N4YzPCCq MYXEUXNQ M2n5coNifXOnczD0bIUh[2ynYY\h[4Uhd2ZiQnPsMVIh[W6mIITo[UBld3ewcnXneYxifGmxbjDv[kBD[2xveFygZY5lKE2lbD2x M37DOlI3Ozl{M{Oy
JURKAT MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV2xNFAuOTByMDDuUS=> NHfocFM1QCCq M{XUWGROW09? NXPZOYVpUUN3ME25OVXDuTlwMzDuUS=> MVmyOlE4OjJ4OR?=
LOUCY NVfJUGJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vKS|ExOC1zMECwJI5O M4PPVVQ5KGh? NY\lNYtbTE2VTx?= NHTrOpZKSzVyPUOyMljDuTFyLkmgcm0> NIfycHgzPjF5MkK2PS=>
WM-115 MXfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1\WTFExOMLibl2= NXmyeVZPPzJiaB?= NUjGV5Nx\W6qYX7j[ZMh[3W{Y4XtbY4ucW6mdXPl[EBidnSrLYP1dpZqfmGuwrC= MUGyOlEyPjd5Nh?=
B16 M{X2OmNmdGxiVnnhZoltcXS7IFHzd4F6 MVyxNFDDqG6P NWXTe|RtPzJiaB?= MWjlcohidmOnczDjeZJkfW2rbj3pcoR2[2WmIHHueIkue3W{dnn2ZYzDqA>? MlzWNlYyOTZ5N{[=
HL-60  NWT1Sm01T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvHO|IhcA>? MXrJR|UxyqB;IEGwMlchdk1? NUn2eFQ6OjZyNEW2NFk>
MOLM-13  M1[xV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXoRWw4OiCq NYX2S5B2UUN3MNMgQUAzPy57IH7N NYrvTpV[OjZyNEW2NFk>
OCI-AML3 M4HJTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPTVYVbPzJiaB?= M{TxN2lEPTEEoE2gNVk2OCCwTR?= MnPONlYxPDV4MEm=
BCWM.1 MXLBdI9xfG:|aYOgRZN{[Xl? NEXn[3AxNTFwNjFOwG0> Mor2NlQhcA>? M2XGXIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NHvu[mYzPTh7M{K5NC=>
MWCL-1 NFHzSHVCeG:ydH;zbZMhSXO|YYm= NUTzVHg3OC1zLk[g{txO Mo\mNlQhcA>? MYfpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M2fmb|I2QDl|Mkmw
MM.1s NU\KSpB7SXCxcITvd4l{KEG|c3H5 NWTUb4VZOC1zLk[g{txO NVGwOW9[OjRiaB?= NUi1TFBncW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NYLOendoOjV6OUOyPVA>
HCT116 M{\lUGZ2dmO2aX;uJGF{e2G7 M1\qS|MwOTBizszN MYSxNuKhcMLi NF:3N3FFVVOR NVjDdnd1cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKEyFM1KtTWkh[2:wdnXyd4lwdiCjbnSgV3FUXE1zIHTl[5Ji\GG2aX;u MnfvNlU4OTVyMki=
HCT116 BAX BAK1 DKO NG\mNW5HfW6ldHnvckBCe3OjeR?= MkDxN{8yOCEQvF2= M1nmSlEzyqCqwrC= NIXkb|lFVVOR M3;kW4lv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG|ZTDpckBNSzOELVnJJINwdn[ncoPpc44h[W6mIGPRV3ROOSCmZXfyZYRifGmxbh?= MYqyOVcyPTB{OB?=
HCT116 NHvNWYpHfW6ldHnvckBCe3OjeR?= M3zUNlExKM7:TR?= M3TDVlEzyqCqwrC= Ml3oSG1UVw>? NV;JWoxFcW6lcnXhd4V{KEeIUD3MR|NDKHC3bnP0ZS=> NVHVT2MzOjV5MUWwNlg>
HCT116 BAX BAK1 DKO NFrWOY1HfW6ldHnvckBCe3OjeR?= M{DIOFExKM7:TR?= NUjBRYhUOTMEoHlCpC=> MWLEUXNQ NInNWGpqdmO{ZXHz[ZMhT0[SLVzDN2IheHWwY4Th NIjMO3UzPTdzNUCyPC=>
HCT116 MkTqRZV1d3CqYXf5JGF{e2G7 NI\0OG0yOCEQvF2= M4rlZ|EzyqCqwrC= NHG3W3ZFVVOR MnzHbY5lfWOnczDhJINwdXCuZYTlJIF2fG:yaHHnbYMhemW|cH;ud4U> M2[0SFI2PzF3MEK4
HCT116 BAX BAK1 DKO MUjBeZRweGijZ4mgRZN{[Xl? M{njVFExKM7:TR?= M2Dhc|EzyqCqwrC= M13TWGROW09? MWfpcoR2[2W|IHGgZ49ueGyndHWgZZV1d3CqYXfpZ{Bz\XOyb37z[S=> NV:0TYo3OjV5MUWwNlg>
U937 NHzlRXVCeG:ydH;zbZMhSXO|YYm= NHe4XnoxNjF{NT2yJO69VQ>? MmjyNlQhcA>? MmDq[Y5p[W6lZYOgSGhCN1hvMUGtbY5lfWOnZDDhdI9xfG:|aYO= NF;0eoczPTdzNECyOC=>
U937  MX;BdI9xfG:|aYOgRZN{[Xl? NETnSJAxNjVizszN MoKxNlQhcA>? NVrQOWRN\W6qYX7j[ZMh[2ynYY\h[4Uhd2ZiUFHSVEBidmRiY3HzdIF{\S1|IHHzJJdmdGxiYYOgUo95[SCuZY\lcC=> M2\xdlI2PzF2MEK0
HL-60 AAA-Bcl-2 MYnBdI9xfG:|aYOgRZN{[Xl? MWOwMVUh|ryP MYC0PEBp MoPxTWM2OD1yLki3JO69de,:jHnu[JVk\XNiY3XscEBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mo\XNlU4OTF2NkC=
HL-60 EEE-Bcl-2 M{\GU2Fxd3C2b4Ppd{BCe3OjeR?= M3jhXlAuPSEQvF2= NYrpTHRbPDhiaB?= MXnJR|UxRTVizszt89yNKGmwZIXj[ZMh[2WubDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MV[yOVcyOTR4MB?=
U87 MVfGeY5kfGmxbjDBd5NigQ>? M2PUSFUxKM7:TR?= MV2yOEBp NIP4ZXNz\WS3Y3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hdGW4ZXzzJI9nKE2PUD2yMEBOVVBvMUSgZY5lKEKlbD2y NGfVc|UzPTZ4N{[2Ny=>
K562 MoD3R4VtdCCYaXHibYxqfHliQYPzZZk> Mn20NU0yOCEQvF2= NFjKeok1QCCq NHHFdGFFVVOR Mmi4TWM2OD1{Nj63JO69VQ>? NGXMd2szPTV7NkW2NS=>
K562/Mcl -1-IRESBim MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPVeYZKSzVyPUmuN{DPxE1? NED5ZYczPTV|NUmwNC=>
K562/Bcl- 2-IRESBim M{XFZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PDfWlEPTB;MD6zOUDPxE1? NX\zV3dROjV3M{W5NFA>
Jurkat M1fVb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL2VHlKSzVyPUCuOlYh|ryP MXWyOVU{PTlyMB?=
JurkatΔBak M1PM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3n1[GlEPTB-NUCg{txO MmjmNlU2OzV7MEC=
HL60/VCR NFvofm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjheFdKSzVyPkGwNEDPxE1? MWmyOVU{PTlyMB?=
Kasumi-1 M3TOdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\CcotKSzVyPUCuNFEh|ryP NWPPV21POjV3M{W5NFA>
Kasumi-1/ABT NVfmd2VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHkbGhKSzVyPUCuOVEh|ryP NXnSPHY1OjV3M{W5NFA>
THP-1 NIj4TphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXRTWM2OD1zLkK3JO69VQ>? MXuyOVU{PTlyMB?=
U937 NXPTVoNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Xu[2lEPTB;NT6yPUDPxE1? MoXBNlU2OzV7MEC=
C1498 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTucIpKSzVyPU[uNVMh|ryP M{TKSlI2PTN3OUCw
RPMI 8226 M{fMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4riO2lEPTB;MD6yOUDPxE1? MX6yOVU{PTlyMB?=
MM.1S MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkj6TWM2OD1yLkSwJO69VQ>? NHn1[pkzPTV|NUmwNC=>
NCI-H929 NFjmOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInxXGlKSzVyPUG1MlIyKM7:TR?= Mn7nNlU2OzV7MEC=
U266 M4C5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwNkig{txO NXvhd4Y6OjV3M{W5NFA>
MCF-7 NXjSeG41S2WubDDWbYFjcWyrdImgRZN{[Xl? MkexOUDPxE1? NXTUV4FJPDhiaB?= MkDvSG1UVw>? Mmex[Y5p[W6lZYOgeIhmKHOnboPpeIl3cXS7IITvJI9zKHKjZHnheIlwdg>? M17KWlI2PDB7MUK0
MCF-7 NXLrZ21wSXCxcITvd4l{KEG|c3H5 MUm1JO69VQ>? MnHSOE8zPC92ODDo NIW2NIJFVVOR MmjhbY5kemWjc3XzJJRp\SClbHXheoVlKFCDUmC= M1j1W|I2PDB7MUK0
MCF-7 NWj1[ZR3TnWwY4Tpc44hSXO|YYm= MnPYOUDPxE1? NVHHRZozOjRiaB?= M2nzbmROW09? NXHBTYNq\W6qYX7j[ZMhfGinbHX2[Ywhd2ZiTXPsMVEh\XiycnXzd4lwdsLi M4niS|I2PDB7MUK0
MDA-MB 231  NILnU2RHfW6ldHnvckBCe3OjeR?= NEPvXGU2KM7:TR?= MkDvNlQhcA>? M2fO[mROW09? NGnLXIxmdmijbnPld{B1cGWuZY\lcEBw\iCPY3ytNUBmgHC{ZYPzbY9vyqB? M2D6d|I2PDB7MUK0
ZR-75-1  NIWw[JRHfW6ldHnvckBCe3OjeR?= NEL2UoE2KM7:TR?= M2C5WVI1KGh? MWnEUXNQ NITleoNmdmijbnPld{B1cGWuZY\lcEBw\iCPY3ytNUBmgHC{ZYPzbY9vyqB? MWWyOVQxQTF{NB?=
A549 NWnt[nkxS2WubDDWbYFjcWyrdImgRZN{[Xl? MVWwMVIxKM7:TR?= MXy3NkBp M1:2[WROW09? MWHk[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv M2ezdlI2Ozh6N{[y
H1299 NHSzNm5E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NUjYS3c3OC1{MDFOwG0> M1LkdVczKGh? NXGxNoY1TE2VTx?= NUjKOIZV\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= NYHicVlCOjV|OEi3OlI>
HO-8910 MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4GyfFAuOjBizszN M3[0RlczKGh? M1;GN2ROW09? Ml7Q[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? NYLMWJROOjV|OEi3OlI>
HT-29 MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYfldWxsOC1{MDFOwG0> MXm3NkBp M4nBXGROW09? M2XlVIRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? MWGyOVM5QDd4Mh?=
HCT-116 NH25cVZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYPDNYdXOC1{MDFOwG0> M1zCSVczKGh? NUjWeGI1TE2VTx?= MkjB[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? M3\rPVI2Ozh6N{[y
A549 NI\xOGlCeG:ydH;zbZMhSXO|YYm= NVfNclVbOjBizszN NGrTNnI1QCCq MVXEUXNQ Mn\0bY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJIF{eGm{aX6= NHLwV4kzPTN6OEe2Ni=>
H1299 MoL5RZBweHSxc3nzJGF{e2G7 M33RXFIxKM7:TR?= NUfxeo5IPDhiaB?= MoG5SG1UVw>? MWfpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigZZNxcXKrbh?= Ml23NlU{QDh5NkK=
Sc-1 NYe3PIkzS2WubDDWbYFjcWyrdImgRZN{[Xl? MUSwMlAxODFvMTFOwG0> MWq5OkBp Mk\3[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MV2yOVM4OzVyOB?=
OcI-LY18 M17DSGNmdGxiVnnhZoltcXS7IFHzd4F6 NXztTW5xOC5yMECxMVEh|ryP MkjZPVYhcA>? NXLNUVVY\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NWXOeIJSOjV|N{O1NFg>
RL  MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MX[wMlAxODFvMTFOwG0> MkWyPVYhcA>? MmXB[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M1TsUVI2Ozd|NUC4
RKO MmTOR4VtdCCYaXHibYxqfHliQYPzZZk> NVLoTXVPOC1zMDFOwG0> M1\mTFI16oDLaNMg MnvuSG1UVw>? MUXJR|UxRuLCiUK15qCKyrWP MWCyOVMxPDN6Mx?=
Caco-2 NHXYRVdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWKwMVExKM7:TR?= NXnMTYNFOjUkgJnoxsA> NWfwbHd1TE2VTx?= NU\hPGJyUUN3ME2xPU446oDLwsXN Mnn4NlU{ODR|OEO=
DLD1 NV2xRYFYS2WubDDWbYFjcWyrdImgRZN{[Xl? M3HJc|AuOTBizszN NILOV2YzPOLCiXlCpC=> NYjTdG9NTE2VTx?= MVPJR|UxRTF6Lke45qCKyrWP NHTUXFYzPTNyNEO4Ny=>
LS411N M2PkeWNmdGxiVnnhZoltcXS7IFHzd4F6 MoTrNE0yOCEQvF2= MYCyOQKBkWkEoB?= MU\EUXNQ MYHJR|UxRTFzLkS35qCKyrWP MUGyOVMxPDN6Mx?=
SW620 M3TzNWNmdGxiVnnhZoltcXS7IFHzd4F6 MkPoNE0yOCEQvF2= M2riXlI16oDLaNMg NUjVbXJzTE2VTx?= MYTJR|UxRTF{LkK05qCKyrWP MmjCNlU{ODR|OEO=
HCT116 MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3\wXFAuOTBizszN MWWyOQKBkWkEoB?= NGO3NW1FVVOR MkfmTWM2OD1{MD60PgKBkcL3TR?= NFXjR4czPTNyNEO4Ny=>
HaCaT NV7jd2ZiS2WubDDWbYFjcWyrdImgRZN{[Xl? M{HBd|AvOS9zL{GwJO69VQ>? NHq0[|AzPCCq NWfZeJN{TE2VTx?= M13YPYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MUWyOVIyODd7NR?=
A5-RT3 M1rNTGNmdGxiVnnhZoltcXS7IFHzd4F6 NVHJTVlTOC5zL{GvNVAh|ryP NYXiWmdYOjRiaB?= NV\xXWNQTE2VTx?= MUHk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVGyOVIyODd7NR?=
HaCaT MonYSpVv[3Srb36gRZN{[Xl? NUPPOmZkOTEkgJpOwG0> NGXB[GEzPC92ODDo NUXxSnhETE2VTx?= M4XqRolv\HWlZYOgUW1RKGGwZDDEUmEh\nKjZ33lcpRifGmxbh?= M2ezZ|I2OjFyN{m1
A5-RT3 NEe3WIdHfW6ldHnvckBCe3OjeR?= M4rSOlEx6oDLzszN MnnGNlQwPDhiaB?= NVjGVZBNTE2VTx?= MXzpcoR2[2W|IF3NVEBidmRiRF7BJIZz[WevZX70ZZRqd25? MV6yOVIyODd7NR?=
A5-RT3 Ml3SSpVv[3Srb36gRZN{[Xl? Mnj5OUDPxE1? M2jyXlYhcA>? Ml\OSG1UVw>? M1\rSYlv\HWlZYOgeIhmKHKnbHXhd4Uhd2ZibXn0c4Npd26mcnnhcEBxem:2ZXnud{BidmRicnXkeYNmeyClbH;uc4dmdmmlIIP1dpZqfmGuIHnuJIEh[2G|cHHz[U1qdmSncHXu[IVvfCCvYX7u[ZI> NEPLVpIzPTJzMEe5OS=>
U266 NULnPHlVTnWwY4Tpc44hSXO|YYm= MYG1NFAwPzVyIH7N M2L4WlI1NzR6IHi= NWPKVVJsTE2VTx?= NEXwemFld3ewcnXneYxifGW|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm|b3\vdo0> M1u5fFI2OjB6OEi4
RPMI8226 NX7nN4RtTnWwY4Tpc44hSXO|YYm= NWTqdWdQPTByL{e1NEBvVQ>? NYXvco5qOjRxNEigbC=> NEDKeIJFVVOR NHPDTnFld3ewcnXneYxifGW|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm|b3\vdo0> NFnvbpgzPTJyOEi4PC=>
MM.1S NFrNcFVHfW6ldHnvckBCe3OjeR?= M1XINVUxOC95NUCgcm0> M4HaOVI1NzR6IHi= MnTGSG1UVw>? MoXm[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt NEXQSW8zPTJyOEi4PC=>
Clone A NXP2ZlZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Tyc|AvOuLCk{[wJO69VQ>? M4Xh[|czKGh? NEfBcXVFVVOR M{j3VWlEPTB;Nz61JO69VQ>? NHnmRW4zPTJyOEi4Ni=>
CX-1 M4GxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYOwMlLjiJN4MDFOwG0> NYn1W4E2PzJiaB?= NFu0UHBFVVOR NVzmRWFRUUN3ME2xMlgh|ryP NUfqTYtVOjV{MEi4PFI>
LS174T NEPjbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2wMlLjiJN4MDFOwG0> NGjFcHY4OiCq M{TB[mROW09? M2nGbWlEPTB;MUiuN{DPxE1? NXrQ[WlEOjV{MEi4PFI>
HT29 MYnBdI9xfG:|aYOgRZN{[Xl? M1j6d|EwPS9zMDFOwG0> Mn3wOFghcA>? NVPZ[pdY[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYLaU5NMOjVzOUKxPFg>
SW480 NIPOR5RCeG:ydH;zbZMhSXO|YYm= NWDEUGF3OS93L{GwJO69VQ>? NWHFVW1lPDhiaB?= NYLFc3p6[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFrJNm8zPTF7MkG4PC=>
Colo205 NIXTOlVCeG:ydH;zbZMhSXO|YYm= MWixM|UwOTBizszN NGC5[pk1QCCq NX7W[pIy[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{S5VlI2OTl{MUi4
Caco2 MVTBdI9xfG:|aYOgRZN{[Xl? MkG5NU82NzFyIN88US=> Mnu3OFghcA>? MkTpZ4F2e2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M2H0SFI2OTl{MUi4
PCI-13 MmruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f1ZVczKGh? NHzUTpZFVVOR NVjhWIxqT0l3ME2xOUDDuSBzLkig{txO MkfmNlUyOzl|OEe=
PCI-15B NYf4RodGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrTSYs4OiCq NUPodVIzTE2VTx?= M2\vSGdKPTB;MUGgxtEhPC53IN88US=> MUOyOVE{QTN6Nx?=
UM-SCC22B NHXYTJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rYcFczKGh? NFvLSm9FVVOR M{D6emdKPTB;MUmgxtEhOi57IN88US=> MWGyOVE{QTN6Nx?=
UM-SCC47 MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[3NkBp MVHEUXNQ M{\wdmdKPTB;MUmgxtEhOTJwMzFOwG0> NGPaNFUzPTF|OUO4Oy=>
93-VU-147T M2n0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnTZnNHPzJiaB?= NYLM[|RqTE2VTx?= NGXSUXdIUTVyPUSuN{DDuSB|LkWg{txO MVmyOVE{QTN6Nx?=
UD-SCC2 M{TwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV63NkBp MX\EUXNQ NXLFSZNZT0l3ME2yPEDDuSB{Lkmg{txO MkfXNlUyOzl|OEe=
UPCI:SCC90 NXzEUlFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVm3NkBp NVryVJI3TE2VTx?= NFXITVBIUTVyPU[uOkDDuSBzLkWg{txO NGHYcFYzPTF|OUO4Oy=>
RPMI-8226  M{PnNmNmdGxiVnnhZoltcXS7IFHzd4F6 M{nLU|EzPS9{NUCvOVAxKG6P MoPBOFhpyqB? MYHEUXNQ NYDSTlNr\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3PQOlI2ODB6MkCy
OPM-2  M{XTbmNmdGxiVnnhZoltcXS7IFHzd4F6 M3Toc|EzPS9{NUCvOVAxKG6P MmDzOFhpyqB? MWTEUXNQ NUG0[oNW\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MVuyOVAxQDJyMh?=
RPMI-8226  MVnBdI9xfG:|aYOgRZN{[Xl? MlnuNVI2NzJ3MD:1NFAhdk1? M322OlQ5cMLi M4HMUGROW09? MXrpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MXWyOVAxQDJyMh?=
OPM-2  NHLBS3VCeG:ydH;zbZMhSXO|YYm= M3mwc|EzPS9{NUCvOVAxKG6P M{jucVQ5cMLi M3;sZ2ROW09? MVHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmrpNlUxODh{MEK=
COG-LL-319 NFXaNYhHfW6ldHnvckBCe3OjeR?= Ml;sNVAxKG6P MYCxM|MwPiCq MnHGSG1UVw>? NVLKVnNZcW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBO[2xvMTDjcIVifmGpZR?= MXOyOFk2OTR5Mh?=
RS4;11 NIXYT45HfW6ldHnvckBCe3OjeR?= NELt[lEyODBibl2= NH7qNW0yNzNxNjDo NFfzeWxFVVOR NHXBVnZqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JG1kdC1zIHPs[YF3[Wen NGT2S48zPDl3MUS3Ni=>

... Click to View More Cell Line Experimental Data

In vivo In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. [1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. [2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. [5]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence polarization assays:

Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research:

[4]

+ Expand
  • Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114
  • Concentrations: 0.001-10 μM
  • Incubation Time: 48 hours
  • Method:

    SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
  • Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%)
  • Dosages: 20 and 30 mg/kg
  • Administration: For intraperitoneal (i.p.) every day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (122.93 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% Propylene glycol, 5% Tween 80, 65% D5W 30mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 813.43
Formula

C42H45ClN6O5S2

CAS No. 852808-04-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy ABT-737 | ABT-737 supplier | purchase ABT-737 | ABT-737 cost | ABT-737 manufacturer | order ABT-737 | ABT-737 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID